Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1980 Jun;39(3):222–227. doi: 10.1136/ard.39.3.222

Formation of calcium pyrophosphate crystals in vitro: implications for calcium pyrophosphate crystal deposition disease (pseudogout)

P R Hearn 1, R G G Russell 1
PMCID: PMC1000520  PMID: 6251756

Abstract

Little is known about how calcium pyrophosphate dihydrate (CaPPD) crystals form in vivo and give rise to chondrocalcinosis or pseudogout (pyrophosphate arthropathy or calcium pyrophosphate crystal deposition disease). In this study a simple method has been devised to define the conditions necessary for the deposition of crystals in vitro. Crystal formation is monitored by 45Ca in the presence of 1·5 mmol/l Ca and increasing concentrations of inorganic pyrophosphate (PPi) under simulated physiological conditions of pH and ionic strength. Concentrations of PPi required to initiate crystal formation were about 40 mmol/l in the absence and 175 mmol/l in the presence of 0·5 mmol/l Mg2+ at pH 7·4. Less PPi was required at higher pH values. The naturally occurring monoclinic and triclinic forms of CaPPD were produced after prolonged incubation in vitro, but the initial deposits were amorphous or orthorhombic. The physiological significance of these observations is discussed. Since much higher concentrations of PPi are required to form crystals in vitro than are found to occur naturally in synovial fluids from patients with pyrophosphate arthropathy, it is suggested that crystals are more likely to deposit initially within cartilage and that nucleating mechanisms may be important in vivo. Since other workers have observed a slow interconversion of other calcium pyrophosphate crystal forms into monoclinic and triclinic allomorphs under laboratory conditions, the reason why only these 2 forms occur under clinical conditions may reflect the long time available in vivo for the formation of crystals.

Full text

PDF
222

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman R. D., Muniz O. E., Pita J. C., Howell D. S. Articular chondrocalcinosis. Microanalysis of pyrophosphate (PPi) in synovial fluid and plasma. Arthritis Rheum. 1973 Mar-Apr;16(2):171–178. doi: 10.1002/art.1780160206. [DOI] [PubMed] [Google Scholar]
  2. BUNDENS W. D., Jr, BRIGHTON C. T., WEITZMAN G. PRIMARY ARTICULAR-CARTILAGE CALCIFICATION WITH ARTHRITIS (PSEUDOGOUT SYNDROME). J Bone Joint Surg Am. 1965 Jan;47:111–122. [PubMed] [Google Scholar]
  3. Bennett R. M., Lehr J. R., McCarty D. J. Factors affecting the solubility of calcium pyrophosphate dihydrate crystals. J Clin Invest. 1975 Dec;56(6):1571–1579. doi: 10.1172/JCI108239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Camerlain M., McCarty D. J., Silcox D. C., Jung A. Inorganic pyrophosphate pool size and turnover rate in arthritic joints. J Clin Invest. 1975 Jun;55(6):1373–1381. doi: 10.1172/JCI108056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cuervo L. A., Pita J. C., Howell D. S. Ultramicroanalysis of pH, p CO2 and carbonic anhydrase activity at calcifying sites in cartilage. Calcif Tissue Res. 1971;7(3):220–231. doi: 10.1007/BF02062609. [DOI] [PubMed] [Google Scholar]
  6. Hamilton E. B. Diseases associated with CPPD deposition disease. Arthritis Rheum. 1976 May-Jun;19 (Suppl 3):353–357. doi: 10.1002/1529-0131(197605/06)19:3+<353::aid-art1780190708>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  7. Maroudas A. Physicochemical properties of cartilage in the light of ion exchange theory. Biophys J. 1968 May;8(5):575–595. doi: 10.1016/S0006-3495(68)86509-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Maroudas A. Transport of solutes through cartilage: permeability to large molecules. J Anat. 1976 Nov;122(Pt 2):335–347. [PMC free article] [PubMed] [Google Scholar]
  9. McCarty D. J. Calcium pyrophosphate dihydrate crystal deposition disease--1975. Arthritis Rheum. 1976 May-Jun;19 (Suppl 3):275–285. doi: 10.1002/1529-0131(197605/06)19:3+<275::aid-art1780190702>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  10. McCarty D. J., Solomon S. D., Warnock M. L., Paloyan E. Inorganic pyrophosphate concentrations in the synovial fluid of arthritic patients. J Lab Clin Med. 1971 Aug;78(2):216–229. [PubMed] [Google Scholar]
  11. Pita J. C., Blanco L. N., Howell D. S. Determination of total and unbound calcium in nanoliter samples of cartilage fluid and serum. Anal Biochem. 1978 Oct 1;90(1):126–135. doi: 10.1016/0003-2697(78)90015-5. [DOI] [PubMed] [Google Scholar]
  12. Russell R. G., Bisaz S., Fleisch H., Currey H. L., Rubinstein H. M., Dietz A. A., Boussina I., Micheli A., Fallet G. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet. 1970 Oct 31;2(7679):899–902. doi: 10.1016/s0140-6736(70)92070-2. [DOI] [PubMed] [Google Scholar]
  13. Silcox D. C., McCarty D. J., Jr Elevated inorganic pyrophosphate concentrations in synovial fluids in osteoarthritis and pseudogout. J Lab Clin Med. 1974 Apr;83(4):518–531. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES